DOACs vs warfarin / Extraction
Data extraction
Extracted estimates · major bleeding
214 rows 8 outcomes| Study | N (rand.) | Effect (HR) | 95% CI | Follow-up |
|---|---|---|---|---|
RE-LY (dabigatran 150mg) Connolly 2009 |
18,113 ⌖ source | 0.93 ⌖ source | 0.81–1.07 ⌖ source | 2.0 y |
ROCKET-AF (rivaroxaban) Patel 2011 |
14,264 ⌖ source | 1.04 ⌖ source | 0.90–1.20 ⌖ source | 1.9 y |
ARISTOTLE (apixaban) Granger 2011 |
18,201 ⌖ source | 0.69 ⌖ source | 0.60–0.80 ⌖ source | 1.8 y |
ENGAGE AF (edoxaban 60mg) Giugliano 2013 |
21,105 ⌖ source | 0.80 ⌖ source | 0.71–0.91 ⌖ source | 2.8 y |
Every value carries a verbatim source span. A verifier agent confirmed the quote exists in the full text before commit.
Source · ARISTOTLE · Effect (HR)
0.69 major bleeding, apixaban vs warfarin
“The rate of major bleeding was 2.13% per year in the apixaban group, as compared with 3.09% per year in the warfarin group (hazard ratio, 0.69; 95% CI, 0.60 to 0.80; P<0.001).”
Results · p.987, col 2 · PDF table 2
Verifiedmodel: extract-deep
Extraction schema
N randomisedEffect estimate + type95% confidence intervalFollow-up durationOutcome definition